Citation

Dichter ME, Ogden SN, Clyatt KJ, Roberts CB. J. Gen. Intern Med. 2019; ePub(ePub): ePub.

Affiliation

Center for Health Equity Research and Promotion, Crescenz VA Medical Center, Philadelphia, PA, USA.

Copyright

(Copyright © 2019, Holtzbrinck Springer Nature Publishing Group)

DOI

10.1007/s11606-019-05372-1

PMID

31621047

Abstract

HIV pre-exposure prophylaxis (PrEP), a daily pill combining two antiretroviral agents, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), has been shown to be effective in preventing HIV transmission in men and women and is recommended for those at increased risk of HIV.1 Experience of intimate partner violence (IPV) increases HIV risk for women,2 and women receiving care in the Veterans Health Administration (VHA) experience substantial rates of IPV.3 Given this risk and the availability of PrEP as a prevention tool in VHA, we sought to examine the association between recent IPV exposure disclosed to VHA providers through routine screening and HIV diagnosis, testing, and PrEP prescriptions among this population.

Language: en